Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis
Authors:
- Bethany B. MooreBMBethany B. Moore
- Susan MurraySMSusan Murray
- The COMET InvestigatorsTIThe COMET Investigators
Open Access
- 22 December 2014
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 1 (56)
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive deposition of extracellular matrix, worsening dyspnea and eventual mortality. Pathogenesis of IPF is poorly understood and the role inflammation and activated leukocytes play in the disease process is controversial. Previous studies demonstrated that activated leukocyte subsets characterize IPF patients. We sought to validate this observation in a well-defined cohort of 35 IPF patients and to correlate the observed leukocyte phenotypes with robust parameters of disease progression. We demonstrate that in univariate and multivariate analyses, increases in the CD14hi, CD16hi subset of monocytes measured at baseline correlated with disease progression, with a threshold value greater than 0.5% of the total peripheral blood mononuclear cells being a significant predictor for worse outcome. In addition, several T cell subsets, including CD25 expressing CD4 cells, and CXCR3 expressing CD4 and CD8 subsets correlated with disease progression when found in increased percentages in the peripheral blood of IPF patients when sampled at baseline. Somewhat surprising in comparison to previous literature, the CD4 T cells did not appear to have lost expression of the co-stimulatory molecule, CD28, but the CD8 T cells did. Taken together, these results are consistent with the presence of an inflammatory process in IPF patients who eventually progress. However, when longitudinal measurements of these same markers were examined, there was significant heterogeneity of expression and these biomarkers did not necessarily remain elevated in IPF patients with progressive disease. We interpret this heterogeneity to suggest that IPF patients experience episodic inflammatory events, that once triggered, may lead to disease progression. This longitudinal heterogeneity in biomarker analyses may explain why such markers are not consistently measured in all IPF cohorts.Keywords
This publication has 33 references indexed in Scilit:
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Differential expression of monocyte/macrophage- selective markers in human idiopathic pulmonary fibrosisExperimental Lung Research, 2011
- TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid PThe International Journal of Biochemistry & Cell Biology, 2011
- Viral infection and aging as cofactors for the development of pulmonary fibrosisExpert Review of Respiratory Medicine, 2010
- Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on MacrophagesPLOS ONE, 2010
- CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary FibrosisPLOS ONE, 2010
- Blood Monocytes: Development, Heterogeneity, and Relationship with Dendritic CellsAnnual Review of Immunology, 2009
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumoniaEuropean Respiratory Journal, 2005